Has Justin Graff, MD received payments from drug or device companies?

Yes. Drug and device makers reported $85,010 in general payments to Justin Graff, MD across 601 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Justin Graff, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Justin Graff, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Justin Graff, MD

Neurology · Tupelo, MSNPI 1427041664

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $68,977 of the $85,010 with a category attached, or 81.1%. 40 manufacturers reported payments, led by AbbVie at 26.8% of the total. Reporting peaked in 2021 at $34,540 and has fallen 99.9% since, to $35 in 2023. Among neurology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,010in general payments, 2019–2025

Across 601 payments — averaging $141.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$23K
Biohaven Pharmaceuticals, Inc.$19K
Teva Pharmaceuticals USA, Inc.$19K
Pfizer$13K
Biohaven Pharmaceutical Holding Company Ltd.$4K
Biogen$1K
plus $6K from 34 others

What the payments were for

Consulting fees$1,6502%
Speaking & faculty fees$68,97781%
Travel & lodging$4,1985%
Food & beverage$10,16212%
Education$230%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	161	$22,818
Biohaven Pharmaceuticals, Inc.	54	$19,462
Teva Pharmaceuticals USA, Inc.	62	$19,254
Pfizer	15	$12,706
Biohaven Pharmaceutical Holding Company Ltd.	12	$4,014
Biogen	20	$1,079
Acorda Therapeutics, Inc	27	$530
E.r. Squibb & Sons, L.L.C.	2	$503
Livanova USA, Inc.	8	$466
Sanofi	26	$461
AstraZeneca(2 entities)	17	$367
Greenwich Biosciences, Inc.	3	$269
Amgen	14	$267
Lilly USA, LLC	15	$255
Medtronic(2 entities)	17	$238
Supernus Pharmaceuticals, Inc.	21	$226
Amneal Pharmaceuticals LLC	12	$215
SK Life Science, Inc.	12	$214
Avanir Pharmaceuticals, Inc.	14	$185
Lundbeck LLC	6	$169
Tanabe Pharma America, Inc.	9	$166
Genentech USA, Inc.	11	$143
Novartis	7	$130
Neurocrine Biosciences, Inc.	9	$122
Acadia Pharmaceuticals Inc	8	$110
Genentech, Inc.	2	$91
Piramal Critical Care	6	$79
UCB, Inc.	6	$78
Jazz Pharmaceuticals Inc.	3	$67
CSL Behring	5	$63
Catalyst Pharmaceuticals, Inc.	4	$56
Merz North America, Inc.	2	$47
Sunovion Pharmaceuticals Inc.	2	$31
Sanofi-aventis U.S. LLC	2	$28
Assertio Therapeutics, Inc.	2	$25
Merz Pharmaceuticals, LLC	1	$20
Boston Scientific	1	$17
EMD Serono, Inc.	1	$16
Takeda Pharmaceuticals U.S.A., Inc.	1	$13
Bristol Myers Squibb	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NURTEC ODT$22,284
UBRELVY$20,743
AJOVY$18,348
ELIQUIS$13,042
TYSABRI$150
Epidiolex$141
VNS Therapy$135

How this compares

$85,010 in reported general payments places this provider in the 90th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi →

Medicare billing

Part B allowed, 2024

$127,372

Medicare patients

438

Services billed

1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Tupelo

Stephen LandyTupelo$1.9M
Mark FletcherTupelo$41K
Samuel NewellTupelo$10K
Donna HarringtonTupelo$6K
William OakesTupelo$3K
Ali AhmadTupelo$2K
Esther FischerTupelo$2K
Ruth FredericksJackson$943K
Wendell HelvestonJackson$883K
Ronald SchwartzHattiesburg$352K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →